摘要
Abstract
Objective The clinical curative effect and safety between pemetrexed disodium and gemcitabine plus cisplatin for treatment of non-small cell lung cancer (NSCLC) patients were observed and compared to provide reference for chemotherapy of non-small cell lung cancer. Methods 63 patients with NSCLC admitted to our hospital between January 2010 and July 2013 were selected as the subjects of this study. The patients were divided into the observation group (n=37) and the control group (n=26) according to the different treatment methods. The observation group was treated with pemetrexed disodium combined with cisplatin, while the control group was treated with gemcitabine combined with cisplatin. The clinical efficacy and medication safety of the two groups were statistically compared. Results In the observation group, 35 patients were partial remission, accounting for 45.5%, and 31 patients stable, accounting for 40.3%, and 11 patients progressed, accounting for 14.3%. There were no complete recovery patients in the observation group. The total effective rate was 45.5%, and the clini-cal gain rate was 85.8%. In the control group, 25 patients showed partial remission, accounting for 37.9%, 32 patients stable, accounting for 48.5%, and 9 patients progressed, accounting for 13.6%, yet no complete recovery patients. The total effective rate was 37.9%, and the clinical gain rate was 86.4%. The total number of adverse reactions of patients in the observation group was 98 times, third degree and above toxicity 28 times, including bone marrow suppression13 times, gastrointestinal reaction 10 times, and biochemical toxicity 5 times. The total number of adverse reactions of patients in the control group was 143 times, third degree and above toxicity 64 times, including bone marrow suppression 31 times, gastrointestinal reaction 21 times, biochemistry toxicity 12 times. The incidence of adverse reactions in the observation group was significantly lower than in the control group (P<0.05). Conclusion For advanced NSCLC chemotherapy, pemetrexed disodium combined with cisplatin treatment can achieve better therapeutic effect. It also achieves less toxic side effects and good medication safety, so it is a good choice for the clinical treatment of patients with NSCLC.关键词
培美曲塞二钠/吉西他滨/顺铂/非小细胞肺癌/毒副反应Key words
Pemetrexed disodium/Gemcitabine/Cisplatin/Non-small cell lung cancer/Toxic and side effects分类
医药卫生
